UBS Group Increases Guardant Health (NASDAQ:GH) Price Target to $40.00

Guardant Health (NASDAQ:GH) had its target price increased by analysts at UBS Group from $32.00 to $40.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s price objective suggests a potential upside of 43.52% from the company’s current price.

GH has been the subject of a number of other research reports. Piper Sandler boosted their price objective on Guardant Health from $30.00 to $34.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. BTIG Research increased their price target on shares of Guardant Health from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, July 30th. TD Cowen lifted their price objective on shares of Guardant Health from $41.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. The Goldman Sachs Group upped their target price on shares of Guardant Health from $28.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, July 17th. Finally, Stephens reissued an “overweight” rating and set a $44.00 price target on shares of Guardant Health in a report on Friday, May 24th. One equities research analyst has rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, Guardant Health currently has a consensus rating of “Moderate Buy” and an average target price of $39.31.

Guardant Health Trading Down 1.4 %

Shares of NASDAQ:GH opened at $27.87 on Wednesday. Guardant Health has a 52 week low of $15.81 and a 52 week high of $41.06. The company’s 50 day moving average is $30.38 and its two-hundred day moving average is $24.40. The company has a market cap of $3.41 billion, a PE ratio of -7.11 and a beta of 1.13. The company has a current ratio of 5.95, a quick ratio of 5.66 and a debt-to-equity ratio of 16.70.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.10). Guardant Health had a negative return on equity of 246.47% and a negative net margin of 76.34%. The business had revenue of $177.24 million for the quarter, compared to analyst estimates of $162.59 million. During the same period in the prior year, the company posted ($0.67) earnings per share. The company’s revenue was up 29.2% compared to the same quarter last year. Equities analysts predict that Guardant Health will post -3.31 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Guardant Health

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Van ECK Associates Corp lifted its holdings in Guardant Health by 29.4% in the 4th quarter. Van ECK Associates Corp now owns 2,702 shares of the company’s stock valued at $73,000 after purchasing an additional 614 shares in the last quarter. Principal Financial Group Inc. boosted its position in Guardant Health by 10.5% during the fourth quarter. Principal Financial Group Inc. now owns 13,045 shares of the company’s stock worth $353,000 after acquiring an additional 1,240 shares during the last quarter. Wealthcare Advisory Partners LLC grew its stake in Guardant Health by 17.9% in the 4th quarter. Wealthcare Advisory Partners LLC now owns 8,596 shares of the company’s stock worth $233,000 after acquiring an additional 1,308 shares during the period. Oak Ridge Investments LLC raised its holdings in Guardant Health by 8.5% in the 1st quarter. Oak Ridge Investments LLC now owns 18,540 shares of the company’s stock valued at $382,000 after acquiring an additional 1,451 shares during the last quarter. Finally, Quarry LP purchased a new position in shares of Guardant Health during the 2nd quarter worth $44,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.